AstraZeneca Invests C$820 Million to Advance Global Hub & Clinical Delivery
Introduction:
AstraZeneca, a global pharmaceutical company focused on developing innovative medicines, has announced an investment of C$820 million (US$570 million) in Canada. This investment aims to create over 700 highly skilled jobs across various business areas and support the expansion into a larger, modern office facility in the Greater Toronto Area (GTA), Ontario.
Features:
AstraZeneca is advancing its global goal of reaching US$80 billion in revenue and launching 20 new medicines by 2030, with eight already introduced and seven Phase III trial results expected in 2025.
As a leading R&D investor in Canada, the company contributed over C$230 million to R&D in 2023, supporting more than 210 clinical studies. Since 2023, its total investment in Canada has exceeded C$1.3 billion, creating 1,200 high-skilled jobs.
In 2024, AstraZeneca strengthened its oncology pipeline with a C$3 billion acquisition of Fusion Pharmaceuticals, a Hamilton-based biotech specializing in radioconjugates for cancer treatment.
Recognizing Canada’s strong life sciences sector, the company benefits from a skilled workforce, top universities, hospitals, and research institutions.
The Ontario government, through Invest Ontario, is supporting AstraZeneca’s expansion with a C$16.1 million investment, reinforcing the province’s role as a global life sciences hub.
These efforts drive economic growth, advance healthcare innovation, and support the development of new medicines in Canada and beyond.
Specifications:
| Name | AstraZeneca |
| Type | Construction |
| Budget | C$820 million (US$570 million) |
| Year | 2030 |
